Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 8 | Journal of Experimental & Clinical Cancer Research

Fig. 8

From: Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells

Fig. 8

Schematic of the synergistic effects of cl-amidine and docetaxel on p53/Akt/mTOR signaling in regulation of genes associated with cell apoptosis, cell cycle arrest and autophagy. Inhibiting PAD2 reverses p53 degradation, leading to the enhanced p53 nuclear accumulation with docetaxel co-treatment, thus accelerating cell apoptosis and cell cycle arrest. The combination treatment also promotes the autophagy processes by synergistically inhibiting Akt/mTOR signing, leading to the enhanced proliferation inhibition

Back to article page